Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

Press Releases
    • Regulatory
    • All releases
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
December 16, 2022
Non Regulatory

SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA

December 14, 2022
Non Regulatory

SynAct Pharma’s COO sells shares to cover tax on holdings

November 1, 2022
Non Regulatory

SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA

September 30, 2022
Non Regulatory

SynAct Pharma submits IND for US Phase 2a/b clinical trial

September 27, 2022
Non Regulatory

SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA

September 14, 2022
Non Regulatory

Approval of amended study protocol for the Phase 2a study in iMN

August 25, 2022
Non Regulatory

CTA approved for the Phase 2b study EXPAND

August 16, 2022
Non Regulatory

Resomelagon proposed international nonproprietary name (INN) for AP1189

July 21, 2022
Non Regulatory

SynAct Pharma improves the design of the ongoing Phase 2a study in iMN

June 21, 2022
Non Regulatory

SynAct Pharma submits CTA for Clinical Phase 2b Study in RA

May 18, 2022
Non Regulatory

Synact Pharma to present at the ABGSC Life Science Summit

May 4, 2022
Non Regulatory

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

April 1, 2022
Non Regulatory

SynAct publishes prospectus in connection with a fully guaranteed rights issue

January 7, 2022
Non Regulatory

SynAct Pharma appoints Patrik Renblad as CFO

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe